LifeSci Capital Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Maintains Target Price $125
LifeSci Capital has reiterated its Buy rating on Dianthus Therapeutics (DNTH.US) and maintained its target price of $125. The firm's continued endorsement suggests confidence in the company's prospects.
Dianthus Therapeutics Announces Claseprubart Oral and Poster Presentations at AANEM Annual Meeting
Dianthus Therapeutics announced upcoming oral and poster presentations for its investigational therapy, claseprubart, at the AANEM Annual Meeting. These presentations will highlight positive results from the Phase 2 MaGic trial and Phase 3 CAPTIVATE trial, showcasing claseprubart's potential as a new treatment for generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). The company also provided updates on its clinical pipeline, including expected top-line data for other trials in late 2026 and 2028.
Dianthus Therapeutics, Inc. (DNTH) Stock Price, News, Quote & History
This article provides comprehensive financial data for Dianthus Therapeutics, Inc. (DNTH), including its stock price, historical data, and performance metrics against the S&P 500. It also details the company's overview, its clinical-stage biotechnology developments, and analyst insights, such as price targets and recommendations. Key financial highlights and earnings trends are presented to offer a complete picture of the company's market position.
Bank of America Corp DE Takes Position in Dianthus Therapeutics, Inc. $DNTH
Bank of America Corp DE has acquired a new position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH), purchasing 256,833 shares valued at approximately $25 million, representing a 0.47% stake in the company. Despite institutional ownership of 47.53% and a "Moderate Buy" consensus rating from analysts, DNTH shares recently fell by 5.0% after the company reported a quarterly loss that missed consensus estimates. Over the past 90 days, company insiders have sold a significant amount of shares totaling $29.3 million.
Engineers Gate Manager LP Reduces Holdings in Dianthus Therapeutics, Inc. $DNTH
Engineers Gate Manager LP significantly reduced its stake in Dianthus Therapeutics (NASDAQ:DNTH) by 47.1% in Q2 2026, selling 10,330 shares. Despite this reduction, institutional investors collectively own 47.53% of the company. Dianthus Therapeutics shares opened down 4.3% at $96.81, and the company reported a quarterly loss of $0.90 per share, missing analyst estimates, though revenue exceeded expectations.
Dianthus (NASDAQ: DNTH) officer set to sell 20,000 shares
An officer of Dianthus Therapeutics, Edward Carr, has filed a Rule 144 notice to sell up to 20,000 shares of common stock. These shares, valued at $2,049,800, result from an exercise of stock options for cash on September 17, 2026. The sale will be executed through Morgan Stanley Smith Barney LLC, with Dianthus Therapeutics having 55,934,378 shares outstanding as of the referenced date.
Dianthus Therapeutics R&D Head Randhawa Simrat Retains 4,000 Shares After Exercising and Selling Options
Randhawa Simrat, Executive Vice President and Head of Research and Development at Dianthus Therapeutics, exercised options for 23,124 shares on September 1, 2026. Following the exercise, Simrat sold all 23,124 shares, with sale prices ranging from $105.19 to $106.74 per share. After these transactions, Simrat retained 4,000 shares and holds 87,500 derivative securities.
Dianthus stock gains new Buy from Citi (DNTH:NASDAQ)
Citi has initiated a Buy rating on Dianthus Therapeutics (DNTH), citing a multibillion-dollar sales potential for its lead drug, claseprubart. Dianthus is a biotech company focused on developing treatments for autoimmune conditions. The analyst's positive outlook is based on the significant market opportunity for the complement inhibitor.
Officer at Dianthus (NASDAQ: DNTH) lines up 2026 stock sale after option exercise
An officer at Dianthus Therapeutics, Inc. (DNTH), Simrat Randhawa, has filed a Rule 144 notice to sell up to 23,124 shares of common stock on or after September 1, 2026. These shares, valued at an aggregate market value of $2,442,125.64, will be acquired through the exercise of stock options for cash. The sale will be executed via Morgan Stanley Smith Barney LLC on NASDAQ.
Dianthus Therapeutics to Participate in Three Investor Conferences During September
Dianthus Therapeutics, a clinical-stage biotechnology company focused on autoimmune diseases, announced its participation in three investor conferences in September 2026. CEO Marino Garcia and other executives will host one-on-one meetings and participate in fireside chats at the Wells Fargo, Citi's Biopharma, and Cantor Global Healthcare Conferences to discuss the company's progress and vision. Webcasts for the Citi and Cantor events will be available on the company's website.
DNTH Shares Surge 89% Over the Past Six Months: What's Driving It?
Dianthus Therapeutics (DNTH) shares have surged 88.9% in the past six months, driven by investor confidence in its lead asset, claseprubart, and a strong financial position. The company is advancing claseprubart for multiple autoimmune diseases, with pivotal phase III trials underway or planned for gMG and CIDP. Additionally, Dianthus's second pipeline candidate, DNTH212, is progressing through phase I studies for several autoimmune disorders, supported by a robust cash reserve of $1.2 billion.
Bank of America Corp DE Trims Stake in Dianthus Therapeutics, Inc. $DNTH
Bank of America Corp DE significantly reduced its stake in Dianthus Therapeutics (NASDAQ:DNTH) by 59.4% in the first quarter, selling over 276,000 shares but still retaining a holding worth approximately $15.8 million. Despite this, institutional investors collectively own 47.53% of the stock, and analysts maintain a "Moderate Buy" rating with an average price target of $124.27. Recent insider selling has also occurred, with over $29 million worth of shares sold in the last three months, even as the company's stock approaches its 52-week high.
Dianthus Therapeutics director Simon Read sells $326,553 in stock
Dianthus Therapeutics director Simon Read sold 2,778 shares of company stock for $326,553 on August 19, 2026, after exercising stock options under a Rule 10b5-1 trading plan. The sale occurred near the stock's 52-week high, with the company showing a 401% return over the past year. Despite the insider sale, recent news indicates strong analyst confidence due to positive Q2 earnings, the development of DNTH312, and promising clinical trial data for claseprubart.
Dianthus Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Read Simon
This document is a statement of changes in beneficial ownership of securities for Director Read Simon of Dianthus Therapeutics, filed as a Form 4. It indicates transactions related to his holdings in the company.
Eagle Health Investments LP Takes Position in Dianthus Therapeutics, Inc. $DNTH
Eagle Health Investments LP has acquired 131,344 shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) valued at approximately $12.8 million, making it their 20th largest holding. Despite this institutional interest and a "Moderate Buy" consensus rating from analysts, insiders have recently sold a significant amount of stock, totaling nearly $29.6 million. Dianthus Therapeutics reported a quarterly loss but exceeded revenue expectations, and the company is developing complement therapeutics for autoimmune and inflammatory diseases.
Royal Bank of Canada Has $1.60 Million Stock Holdings in Dianthus Therapeutics, Inc. $DNTH
Royal Bank of Canada significantly increased its stake in Dianthus Therapeutics, Inc. by 847.5% in the first quarter, now holding 19,064 shares valued at $1.60 million. Despite the company missing EPS estimates, institutional investors collectively own 47.53% of the stock, and Wall Street analysts maintain a "Moderate Buy" rating with an average price target of $124.27. However, recent insider selling, including by the CEO and a director, totals approximately $29.6 million over the past 90 days.
Handelsbanken Fonder AB Invests $1.49 Million in Dianthus Therapeutics, Inc. $DNTH
Handelsbanken Fonder AB has initiated a $1.49 million position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) during the second quarter of 2026. This investment comes as institutional investors collectively own 47.53% of the company, and analysts maintain a "Moderate Buy" consensus rating with an average price target of $124.27, despite the company missing its quarterly EPS estimates and recent insider stock sales.
Dianthus Therapeutics director Simon Read sells $326,553 in stock By Investing.com
Dianthus Therapeutics director Simon Read sold 2,778 shares of company stock for $326,553 on August 19, 2026, after exercising options. The sale occurred near the stock's 52-week high, and the company has recently reported positive Q2 2026 earnings, advanced its drug pipeline, and received favorable analyst ratings. The transactions were conducted under a Rule 10b5-1 trading plan.
Dianthus Therapeutics director Simon Read sells $326,553 in stock By Investing.com
Dianthus Therapeutics director Simon Read sold 2,778 shares of the company's stock for $326,553, after exercising options at a lower price, all under a Rule 10b5-1 trading plan. This transaction occurred as the stock trades near its 52-week high, with InvestingPro suggesting it is overvalued. The company recently reported strong Q2 2026 earnings, announced a new drug development, initiated a Phase 3 trial, and received reiterated "Strong Buy" ratings and increased price targets from several analysts.
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Average Rating of "Moderate Buy" from Analysts
Dianthus Therapeutics (NASDAQ:DNTH) has received a consensus "Moderate Buy" rating from fourteen analysts, with an average 12-month price target of $124.27. Despite shares trading near a 52-week high, the company remains unprofitable, reporting a quarterly loss of $0.90 per share, and insiders have sold approximately $29.3 million worth of shares in the past 90 days. Institutional investors, however, have shown significant activity, with some increasing their stakes in the company.
TimesSquare Capital Management LLC Acquires Shares of 166,357 Dianthus Therapeutics, Inc. $DNTH
TimesSquare Capital Management LLC has acquired 166,357 shares of Dianthus Therapeutics (NASDAQ:DNTH) valued at approximately $16.2 million, representing 0.30% of the company. Despite significant insider selling totaling $29.3 million over the past 90 days and a missed EPS consensus, analysts maintain a "Moderate Buy" rating with an average price target of $124.27. Dianthus Therapeutics' stock opened at $114.86, close to its 52-week high, with institutional investors owning 47.53% of the shares.
SCS Capital Management LLC Takes Position in Dianthus Therapeutics, Inc. $DNTH
SCS Capital Management LLC recently acquired a new stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) worth approximately $914,000, contributing to 47.53% institutional ownership. Despite positive analyst sentiment with a "Moderate Buy" consensus and an average price target of $124.27, company insiders have sold a significant number of shares, valued at about $29.3 million, over the past 90 days. Dianthus Therapeutics also reported a quarterly EPS miss of -$0.90 against an expected -$0.85.
Dianthus Therapeutics (DNTH) director exercises options and sells 2,777 shares under 10b5-1 plan
Dianthus Therapeutics director Simon Read exercised stock options for 2,777 shares at $18.36 per share and subsequently sold all 2,777 common shares in six open-market transactions, with weighted average prices ranging from $107.11 to $111.77. These transactions were carried out pursuant to a Rule 10b5-1 trading plan adopted on May 8, 2026. Following these trades, Read retains 22,223 option shares from the same award, which vest in annual installments until May 22, 2035.
Walleye Capital LLC Takes Position in Dianthus Therapeutics, Inc. $DNTH
Walleye Capital LLC initiated a new position in Dianthus Therapeutics (NASDAQ:DNTH) worth approximately $1.74 million during the second quarter. Other institutional investors also adjusted their holdings, bringing total institutional ownership to 47.53%. Despite the company reporting an adjusted loss per share that missed estimates, analysts maintain a "Moderate Buy" rating with an average price target of $124.27, reflecting confidence in its future.
Dianthus Therapeutics stock hits 52-week high at 114.64 USD
Dianthus Therapeutics Inc. (DNTH) stock has reached a new 52-week high of $114.64, trading at $114.68, marking a 441% increase over the past year and 166% year-to-date. This surge follows recent positive developments, including the announcement of second-quarter 2026 earnings, the introduction of a new bifunctional fusion protein DNTH312, and the initiation of a Phase 3 trial for claseprubart. Analysts have responded positively, with multiple firms reiterating strong buy ratings and raising price targets, though InvestingPro suggests the shares may be overvalued.
Dianthus Therapeutics stock hits 52-week high at 114.64 USD By Investing.com
Dianthus Therapeutics (DNTH) stock has reached a new 52-week high of $114.64, driven by a 441% increase over the past year and 166% year-to-date. This surge follows positive developments including upward revisions of earnings estimates by analysts, the introduction of a new bifunctional fusion protein DNTH312, and progress in clinical trials for claseprubart in Myasthenia Gravis and CIDP. Despite potential overvaluation according to InvestingPro, analysts maintain strong buy ratings, citing favorable clinical data and market conditions.
Sirenia Capital reveals 1.70M-share DNTH stake in Dianthus Therapeutics (DNTH)
Sirenia Capital Management LP and Alex Silverstein have reported a beneficial ownership of 1,696,751 shares in Dianthus Therapeutics Inc. (DNTH), representing 3.1% of the company's outstanding common stock. This figure includes 510,400 shares issuable upon the exercise of call options. The filing indicates shared voting and dispositive power over these shares and is an amendment to a Schedule 13G, confirming ownership of less than 5% of the class.
Dianthus Therapeutics (DNTH): Wellington group discloses 3.23M-share, 5.9% passive stake
Wellington Management entities have disclosed a passive beneficial ownership stake of approximately 5.9% (3,229,882 shares) in Dianthus Therapeutics (DNTH) through a Schedule 13G filing. The shares are held by clients of various Wellington investment advisers, with Wellington reporting shared voting and dispositive power but no sole voting or dispositive power. No single client holds more than five percent of the class.
Dianthus therapeutics director Simon Read sells $304k in stock
Simon Read, a director at Dianthus Therapeutics Inc. (NASDAQ:DNTH), sold approximately $304,231 worth of common stock on August 10, 2026. This transaction involved the exercise of stock options and subsequent sale of 2,777 shares, executed under a Rule 10b5-1 trading plan. Following these sales, Mr. Read no longer holds direct beneficial ownership in the company, whose stock has seen a 445% gain in the past year but is considered overvalued by InvestingPro.
Dianthus therapeutics director Simon Read sells $304k in stock
Simon Read, a director at Dianthus Therapeutics, sold approximately $304,231 worth of common stock on August 10, 2026, after exercising stock options. These transactions, conducted under a Rule 10b5-1 trading plan, leave Mr. Read with no direct beneficial ownership in the company. The sale occurred while the stock was trading near its 52-week high, following a significant 445% gain over the past year.
Dianthus Therapeutics SVP Adam Veness sells $2.2m common stock
Adam M. Veness, SVP of Dianthus Therapeutics (NASDAQ:DNTH), sold over $2.2 million worth of company common stock and acquired $357,599 through option exercises. These transactions occurred on August 7 and 10, 2026, under a pre-established trading plan, as the stock trades near its 52-week high after a significant gain.
Dianthus Therapeutics Insider Sold Shares Worth $844,822, According to a Recent SEC Filing
An insider at Dianthus Therapeutics (DNTH) has sold shares valued at $844,822, as disclosed in a recent SEC filing. This transaction, reported on August 11, 2026, follows another recent insider sale of $2,208,833. Dianthus Therapeutics is a clinical-stage biotechnology company developing therapies for severe autoimmune diseases, with its lead candidate claseprubart currently in Phase 3 trials.
Dianthus Therapeutics (NASDAQ:DNTH) SVP Sells 16,167 Shares of Stock
Dianthus Therapeutics (NASDAQ:DNTH) SVP Adam Veness sold 16,167 shares of the company's stock for approximately $1.78 million, reducing his stake by over 80%. This transaction occurred as the company's shares fell 3.0% to $108.49, following a quarterly earnings report that missed EPS estimates but exceeded revenue forecasts. Despite the insider sale and EPS miss, analyst sentiment remains broadly positive, with a "Moderate Buy" consensus and an average price target of $124.27.
Simon Read Sells 2,777 Shares of Dianthus Therapeutics (NASDAQ:DNTH) Stock
Dianthus Therapeutics Director Simon Read sold 2,777 shares of the company's stock for over $304,000, reducing his stake by 50%. This transaction occurred as DNTH shares experienced a 3.0% decline following a quarterly earnings report that missed EPS estimates, despite revenue exceeding expectations. Analysts maintain a "Moderate Buy" rating for Dianthus Therapeutics, with an average price target of $124.27.
Anne Mcgeorge Sells 7,750 Shares of Dianthus Therapeutics (NASDAQ:DNTH) Stock
Dianthus Therapeutics director Anne Mcgeorge sold 7,750 shares of DNTH stock for over $844,000, reducing her direct ownership by 86.11%. Despite the sale, which occurred near the stock's 12-month high, analysts maintain a "Moderate Buy" rating with a consensus price target of $124.27. The company recently reported a quarterly loss but exceeded revenue expectations, with institutional investors holding 47.53% of the stock.
DNTH insider Adam M. Veness plans Rule 144 sale of 16,167 shares
Adam M. Veness, an insider at Dianthus Therapeutics, Inc. (DNTH), has filed a Rule 144 notice to sell 16,167 common shares valued at $1,760,909.64. The transaction, scheduled for August 10, 2026, involves an exercise of stock options for cash on the same date and will be handled by Morgan Stanley Smith Barney LLC Executive Financial Services on NASDAQ. This planned sale follows previous 10b5-1 plan sales by Veness in June and August 2026.
Dianthus Therapeutics, Inc. /DE/ SEC Filing (Aug 10, 2026)
Dianthus Therapeutics, Inc. /DE/ filed a Form 144 with the SEC on August 10, 2026, indicating a proposed sale of 5,550 shares of common stock with an aggregate market value of $624,375.00 through Jefferies LLC. The shares were acquired on May 22, 2025, via a stock option exercise. The filing details information about the securities to be sold and the acquisition circumstances.
Dianthus Therapeutics, Inc. /DE/ SEC Filing (Aug 10, 2026)
This article reports on a Form 144 SEC filing by Dianthus Therapeutics, Inc. (DNTH) on August 10, 2026. The filing indicates Anne M McGeorge, a director, is proposing to sell 7,750 shares of common stock with an aggregate market value of $844,130, acquired through the exercise of stock options on the same date. The securities are to be sold via Morgan Stanley Smith Barney LLC on NASDAQ.
California State Teachers Retirement System Raises Stock Holdings in Dianthus Therapeutics, Inc. $DNTH
The California State Teachers Retirement System significantly increased its stake in Dianthus Therapeutics (DNTH) by 155.5% in the first quarter, now owning 40,584 shares valued at $3.4 million. Despite this institutional confidence and generally positive analyst ratings, the company faces risks including ongoing losses, missing quarterly EPS expectations, and substantial insider selling. Dianthus Therapeutics focuses on developing complement therapeutics for autoimmune and inflammatory diseases and currently holds a "Moderate Buy" consensus rating among analysts.
Dianthus Therapeutics Inc expected to post a loss of 86 cents a share - Earnings Preview
Dianthus Therapeutics Inc is projected to report a loss of 86 cents per share. This information comes from an earnings preview provided by Reuters, accessible through TradingView News. The full article and more content from various news sources are available with an unlimited access subscription on TradingView.
Dianthus Therapeutics CEO Marino Garcia sells $17.9m in shares By Investing.com
Marino Garcia, CEO of Dianthus Therapeutics (NASDAQ:DNTH), sold 166,000 shares totaling approximately $17.95 million on August 7, 2026, following the exercise of stock options. The sale occurred near the stock's 52-week high after a significant 481% return, aligning with an analyst valuation suggesting the stock is overvalued. Dianthus also recently announced a Phase 3 EMERGE trial and received positive analyst ratings from Raymond James, Guggenheim, and TD Cowen.
Dianthus Therapeutics CEO Marino Garcia sells $17.9m in shares
Dianthus Therapeutics CEO Marino Garcia sold approximately $17.95 million worth of common stock on August 7, 2026, through a pre-planned trading strategy. This sale occurred while the stock was trading near its 52-week high after a significant 481% return over the past year. Concurrently, Dianthus Therapeutics announced the initiation of its Phase 3 EMERGE trial and received positive analyst ratings from Raymond James, Guggenheim, and TD Cowen.
Dianthus Therapeutics, Inc. /DE/ SEC Filing (Aug 7, 2026)
This article reports on Dianthus Therapeutics, Inc.'s SEC Form 144 filing from August 7, 2026. The filing indicates a proposed sale of 40,000 shares of common stock with an aggregate market value of $4,396,800.00, resulting from the exercise of stock options. The filing has a neutral impact and sentiment according to AI-generated analysis.
Dianthus Therapeutics CEO Marino Garcia reports disposal of 166,000 common shares worth $17.97 million
Dianthus Therapeutics CEO and President Marino Garcia exercised options for 166,000 shares at $8.44 each, increasing his direct holdings. Subsequently, he sold these 166,000 shares at prices ranging from $107.49 to $110.76, reducing his direct common stock holdings to 65,292 shares. The total value of the shares disposed was approximately $17.97 million.
Marino Garcia Sells 166,000 Shares of Dianthus Therapeutics (NASDAQ:DNTH) Stock
Dianthus Therapeutics CEO Marino Garcia sold 166,000 shares of the company's stock for approximately $17.95 million, reducing his direct ownership by 71.77%. The sale occurred on August 7th, with shares trading at $108.11 on average. Despite missing recent earnings estimates, the company's stock is near its 12-month high, and analysts maintain a "Moderate Buy" rating with an average price target of $124.27.
Dianthus Therapeutics (DNTH): T. Rowe Price reports 7.1% stake in common stock
T. Rowe Price Investment Management, Inc. has reported a 7.1% stake in Dianthus Therapeutics Inc.'s common stock, totaling 3,888,456 shares. The investment firm holds sole voting power over 3,884,903 shares and sole dispositive power over all 3,888,456 shares. Despite this, T. Rowe Price explicitly denies beneficial ownership and states the securities were acquired and are held in the ordinary course of business, not for influencing control of the issuer.
Dianthus Therapeutics (DNTH): T. Rowe Price reports 12.1% ownership stake
T. Rowe Price Investment Management, Inc. has reported a beneficial ownership stake of 12.1% in Dianthus Therapeutics Inc., amounting to 6,632,303 shares of common stock. The firm maintains sole voting power over 6,454,315 shares and sole dispositive power over all 6,632,303 shares. Despite the filing, T. Rowe Price explicitly denies beneficial ownership, stating the report should not be construed as an admission.
DIANTHUS THERAPEUTICS INC : RAYMOND JAMES RAISES TARGET PRICE TO $131 FROM $125
Raymond James has increased its target price for Dianthus Therapeutics Inc. to $131 from $125. The article, sourced from Reuters, indicates this change in financial outlook for the company. The content primarily highlights this price target adjustment.
Dianthus Therapeutics, Inc. Stock 12‑Month Price Target Raised to $133.79, Implies 21% Upside
The average 12-month price target for Dianthus Therapeutics, Inc. (DNTH) stock has increased from $129.77 to $133.79, according to 14 analysts. This updated target suggests a potential upside of approximately 21% from its August 4th closing price. The consensus rating for DNTH remains a "Buy" from 16 covering analysts.
Dimensional Fund Advisors LP Purchases 114,767 Shares of Dianthus Therapeutics, Inc. $DNTH
Dimensional Fund Advisors LP increased its stake in Dianthus Therapeutics (NASDAQ:DNTH) by 54.5%, purchasing 114,767 additional shares to own a total of 325,440 shares. This move comes despite the company missing its quarterly earnings estimates, with analysts maintaining a "Moderate Buy" consensus and an average price target of $120.09. Meanwhile, company insiders have sold a significant amount of shares recently, totaling approximately $8.0 million over the past 90 days.
